Unable to display view head.php file not found.
The Figure shows the primary results of RE-LY.[96] Dabigatran 150 bid (black line) had a statistically significantly lower probability of the composite endpoint of stroke and systemic embolism than did warfarin. Dabigatran 110 mg bid (dark blue line) was non-inferior to warfarin (light blue line), with both of these latter two having a similar probability of endpoint events.
Reiffel JA. Am J Med 2013; 126: 00-00.
[96] Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.